Publications by authors named "H Derrien"

Claim this Profile
A
ALIDHE phase 3b study design: ivosidenib + azacitidine in adults with newly diagnosed mutant acute myeloid leukemia.
Paresh Vyas, Sam Salek, Susana Vives, Christian Recher, Hartmut Döhner, Hélène Derrien

Future Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient involvement in the design of ALIDHE: a study of ivosidenib + azacitidine in newly diagnosed mutant AML.
Samantha Nier, Jana Pelouchova, Ralph Hills, Sam Salek, Hélène Derrien

Future Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cellular origin and clonal evolution of human dedifferentiated liposarcoma.
Nadège Gruel, Chloé Quignot, Laëtitia Lesage, Sophie El Zein, Sylvie Bonvalot, Héloïse Derrien

Nat Commun· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PLK1 Inhibitor Onvansertib Enhances the Efficacy of Alpelisib in -Mutated HR-Positive Breast Cancer Resistant to Palbociclib and Endocrine Therapy: Preclinical Insights.
Sreeja Sreekumar, Elodie Montaudon, Davis Klein, Migdalia E Gonzalez, Pierre Painsec, Héloise Derrien

Cancers (Basel)· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance.
Mandy Lawson, Natalie Cureton, Susana Ros, Azadeh Cheraghchi-Bashi, Jelena Urosevic, Heloise Derrien

Cancer Res· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis